Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

赛马鲁肽 恩帕吉菲 医学 2型糖尿病 二甲双胍 中止 随机对照试验 糖尿病 内科学 胃肠病学 泌尿科 利拉鲁肽 内分泌学
作者
Helena W. Rodbard,Julio Rosenstock,Luís Henrique Santos Canani,Chaicharn Deerochanawong,Janusz Gumprecht,Søren Lindberg,Ildiko Lingvay,ANETTE L. SØNDERGAARD,Marianne Bach Treppendahl,Eduard Montanya,Pablo Jordão Alcântara Cruz,Luis De Loredo,Cecilia Luquez,Maria Alejandra Moisello,Gustavo Akerman Augusto,Marise Lazaretti Castro,Luís Henrique Santos Canani,Branko Akrap,Tomislav Bulum,Dario Rahelić
出处
期刊:Diabetes Care [American Diabetes Association]
卷期号:42 (12): 2272-2281 被引量:314
标识
DOI:10.2337/dc19-0883
摘要

Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium-glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin.Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product without rescue medication) in all randomized patients.Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the empagliflozin group completed the trial. Oral semaglutide provided superior reductions in HbA1c versus empagliflozin at week 26 (treatment policy -1.3% vs. -0.9% [-14 vs. -9 mmol/mol], estimated treatment difference [ETD] -0.4% [95% CI -0.6, -0.3] [-5 mmol/mol (-6, -3)]; P < 0.0001). The treatment difference in HbA1c significantly favored oral semaglutide at week 26 for the trial product estimand (-1.4% vs. -0.9% [-15 vs. -9 mmol/mol], ETD -0.5% [95% CI -0.7, -0.4] [-6 mmol/mol (-7, -5)]; P < 0.0001) and at week 52 for both estimands (P < 0.0001). Superior weight loss was not confirmed at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product -4.7 vs. -3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide.Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
淡定的依瑶完成签到,获得积分10
刚刚
江璃发布了新的文献求助10
2秒前
3秒前
4秒前
美丽的安珊完成签到,获得积分10
5秒前
5秒前
7秒前
Gilana完成签到,获得积分10
7秒前
xyh发布了新的文献求助10
7秒前
江璃完成签到,获得积分10
8秒前
TT发布了新的文献求助10
8秒前
美梦成真完成签到,获得积分10
9秒前
Gakay完成签到,获得积分10
9秒前
量子星尘发布了新的文献求助10
10秒前
szj完成签到,获得积分0
11秒前
旦皋完成签到,获得积分10
11秒前
赘婿应助花壳在逃野猪采纳,获得10
12秒前
卷卷完成签到,获得积分10
14秒前
JSY完成签到 ,获得积分20
14秒前
xyh完成签到,获得积分10
15秒前
小曾应助Florencia采纳,获得10
16秒前
神外王001完成签到 ,获得积分10
16秒前
21秒前
你是谁完成签到,获得积分10
22秒前
majf完成签到,获得积分10
23秒前
linhanwenzhou完成签到,获得积分10
23秒前
JSY关注了科研通微信公众号
23秒前
853225598完成签到,获得积分10
23秒前
798完成签到,获得积分10
24秒前
善学以致用应助董怼怼采纳,获得10
24秒前
妍儿完成签到,获得积分20
25秒前
隐形曼青应助高大的水壶采纳,获得10
25秒前
马哥二弟无敌完成签到 ,获得积分10
26秒前
27秒前
Florencia完成签到,获得积分10
27秒前
务实颜完成签到 ,获得积分10
27秒前
27秒前
amberzyc应助小远采纳,获得10
28秒前
28秒前
29秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029